The Claim
In a woman with cystic fibrosis and obesity, initiation of elexacaftor/tezacaftor/ivacaftor resulted in a 15.0 kg weight gain and worsening glycemic control, leading to the initiation of semaglutide therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A woman with cystic fibrosis and obesity gained 15.0 kilograms and experienced increased blood sugar levels after starting elexacaftor/tezacaftor/ivacaftor, which led to her beginning semaglutide treatment.
See the scientific wording
In a woman with cystic fibrosis and obesity, initiation of elexacaftor/tezacaftor/ivacaftor (ETI) was followed by a 15.0 kg weight gain and worsening glycemic control, prompting the initiation of semaglutide therapy.
A medicine that fixes a faulty protein in the lungs causes the body to absorb more food and store more fat, leading to rapid weight gain and higher blood sugar. To fix this, another medicine is given that reduces appetite and forces the body to break down muscle and fat for energy, which lowers blood sugar but also weakens muscles and bones.
What the research says
1 studyA woman with cystic fibrosis gained a lot of weight and her blood sugar got worse after starting a new medicine called ETI, so her doctors gave her another medicine, semaglutide, to help her lose weight and lower her blood sugar — and that’s exactly what happened in this study.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.